BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Thursday, September 10, 2026
📌TL;DR
BMS' arlo-cel (arlocabtagene autoleucel), a GPRC5D directed CAR T, met the overall response rate primary endpoint of the registrational Phase 2 QUINTESSENTIAL trial in quadruple class exposed relapsed and refractory multiple myeloma, with complete response secondaries also met; every figure was withheld for an unnamed congress, per the September 8 release.
The FDA granted accelerated approval to Bayer's Hyrnuo (sevabertinib) as a first line treatment for HER2 mutant non squamous non small cell lung cancer on a 75% objective response rate in the 69 patient treatment naive cohort of SOHO-01, per Bayer; confirmation rides on Phase 3 SOHO-02.
HHS made Michael Davis permanent director of CDER and Karim Mikhail permanent director of CBER, and created a Deputy Commissioner for Technology and Artificial Intelligence role for Jared Seehafer, per BioSpace and Fierce Pharma.
Three private rounds announced September 9 total $550 million by our arithmetic: Solstice Oncology's $225M Series A around Harbour BioMed's CTLA-4 antibody porustobart, Encoded Therapeutics' $275M Series F for the ETX101 Dravet gene therapy, and Kura Oncology's $50M spinout Caspian Therapeutics, with Eli Lilly participating.
BioMarin published Phase 3 hypochondroplasia results in NEJM Evidence: Voxzogo improved annualized growth velocity by 2.33 cm per year versus placebo; a US filing has been submitted.
Day two closes: AMGN 391.27, down 0.5%; NVS ADRs 137.48, down 0.2%; AMLX 32.40, down 4.4%, an eighth straight close below the $35.50 offer price.
⚡ Executive Takeaway
Tuesday now stands as the day three major sponsors, Novartis, Amgen and Bristol Myers Squibb, each announced a late stage result and kept every number. That is not a coincidence of timing; it is a disclosure strategy revealing itself. A topline that says met without saying by how much converts a scientific claim into an IOU, redeemable at a congress the sponsor picks, on a date the sponsor controls.
Notice who could not play the game this week: Bayer published its full response table on Wednesday, because an approval forces a label to say what the drug did. Regulators still extract numbers; press releases no longer volunteer them. So the working rule gets sharper: price the claim, not the adjective, and charge rent for every week an IOU stays undated. Three of the week's five withheld datasets currently carry no due date at all, and the market shrugged at all of them today, which is exactly how mispricings sit until a congress program goes live. The Pro brief ranks the ledger. 👉 Read Full Analysis
🧬 Cell Therapy
BMS' GPRC5D CAR T cleared its registrational myeloma trial, and the numbers went where numbers go now. BMY
Arlo-cel (arlocabtagene autoleucel) met the overall response rate primary endpoint of the registrational Phase 2 QUINTESSENTIAL trial in quadruple class exposed relapsed and refractory multiple myeloma, patients already through a proteasome inhibitor, an anti CD38 antibody, an immunomodulatory agent and a BCMA therapy. Complete response secondaries were met too, and every figure is being held for an unnamed medical meeting, per the September 8 release that surfaced in Wednesday's trade coverage. The target is the story: GPRC5D is a different antigen from BCMA, which both approved myeloma CAR Ts hit, so arlo-cel is aimed at patients who have already burned the BCMA option. BMO called it a "key derisking event," per BioSpace, which also pegs Arcellx and Gilead's rival anito-cel at a December 23 FDA action date. Same sponsor, same modality, two different worlds: BMS' autoimmune CAR T zola-cel remains paused with no primary document, while its oncology CAR T just went registrational.
🎗️ Oncology
Bayer's Hyrnuo went first line on a number Bayer was happy to publish.
The FDA granted accelerated approval to Hyrnuo (sevabertinib) as a first line treatment for HER2 mutant non squamous non small cell lung cancer, resting on a 75% objective response rate in the 69 patient treatment naive cohort of the SOHO-01 trial, with 73% of responses lasting six months or longer, per Bayer's release. Confirmation rides on the Phase 3 SOHO-02 study. The label lands about seven months behind Boehringer Ingelheim's Hernexeos in a mutation found in roughly 2% to 4% of non small cell lung cancers, per Fierce Pharma, so the real fight is over HER2 testing at diagnosis. It is the second accelerated oncology approval in six days, and the contrast with the week is the point: response rate surrogates still buy approvals where unmet need is high and a confirmatory trial is attached. The FDA's surrogate ledger and the market's are being marked very differently right now.
🏛️ Policy
The FDA's drug and biologics chiefs lost their acting labels.
HHS made Michael Davis permanent director of CDER and Karim Mikhail permanent director of CBER, roles both had held in acting capacity since mid May, and created a Deputy Commissioner for Technology and Artificial Intelligence post for Jared Seehafer, per BioSpace and Fierce Pharma. RBC Capital Markets read the moves as stability. The read that matters for this page: three contested review reversals in two months all happened under acting center leadership, and commissioner nominee Heidi Overton, still awaiting a hearing, is expected by analysts to delegate heavily to these now permanent directors. If review variance was partly a leadership vacuum artifact, the variable just changed, and the next contested file will tell us how much.
💰 Capital Markets
Three private rounds, $550 million, one Wednesday.
Solstice Oncology launched with a $225 million Series A led by RA Capital to take Harbour BioMed's next generation CTLA-4 antibody porustobart into a neoadjuvant colon cancer trial with Keytruda; Harbour's roughly $105 million at signing splits into $55 million of cash and a $50 million equity stake, with up to $1.1 billion in milestones on ex China sales. Encoded Therapeutics raised a $275 million Series F co led by GV to push its ETX101 gene therapy through a pivotal Dravet syndrome study. And Kura Oncology spun out Caspian Therapeutics with $50 million, Eli Lilly participating, to test menin inhibition as a beta cell regeneration approach to diabetes, with Kura keeping about half. All three releases are dated September 9; the sum is our arithmetic. A China NewCo, a late stage gene therapy round and a pharma seeded spinout in one session is the capital markets barbell working at full width.
🧪 Rare Disease
BioMarin put its hypochondroplasia case in print. BMRN
Phase 3 CANOPY-HCH-3 results published in NEJM Evidence show Voxzogo (vosoritide) improved annualized growth velocity by 2.33 cm per year versus placebo in children with hypochondroplasia, with no treatment related serious adverse events reported, per BioMarin. A US filing has been submitted, targeting a 2027 launch into roughly 14,000 addressable children by the company's count. Achondroplasia has turned into a knife fight with Ascendis' Yuviwel, approved in March; hypochondroplasia would be Voxzogo's alone for a while, and BioMarin collects a royalty on Yuviwel's US sales either way, per Fierce Pharma.
📉 The Tape
Day two: nothing bounced. AMGN | NVS | AMLX
Official September 9 closes: AMGN 391.27, down another 0.5% after Tuesday's 10.1% drop, with no round trip and no Amgen statement on olpasiran found in tonight's sweep; NVS ADRs 137.48, down 0.2%, holding the post crash level; AZN 156.94, down 1.9%; NVO 44.56, down 1.3%; IONS 56.02, down 1.2%; RPRX unchanged at 60.59; BSX flat at 44.96; BMY 64.41, down 0.4%. AMLX closed at 32.40, an eighth straight close below the $35.50 offer price, with the offering's closing still unannounced in tonight's check and the greenshoe forcing paperwork by about September 18. The Lilly and Sangamo close also remains unconfirmed by any primary. No cause assigned to any move without a company disclosure. The surrogate discount has now held for two full sessions; Friday we run the tally.
📋 Quick Hits
Labcorp acquired MLM Medical Labs, a central and specialty lab group with sites in Memphis, Mönchengladbach and South Africa, terms undisclosed, calling itself the only central lab provider with a wholly owned network on four continents (MedTech Dive). A quiet CRO services consolidation data point.
Merck is cutting another round of positions at its New Jersey headquarters toward its 2027 cost target; Fierce Pharma and BioSpace report slightly different counts and we found no primary notice tonight, so we leave the number out.
Sandoz sketched a "vast and vertically integrated" supply chain to support its 100 biosimilar ambition, per BioSpace, extending the golden decade pitch it made Tuesday.
Oura's IPO filing shows 5 million paid members, 3.1 million rings sold in the fiscal year, and $60.8 million of net income in the nine months to June 30, per MedTech Dive's read of the S-1.
Evommune discontinued its MRGPRX2 antagonist after a second Phase 2 miss, and Schrödinger stood up an immunology spinout, Tectora Therapeutics (Fierce Biotech).
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full SOHO-01 Cohort F response table behind Hyrnuo's first line label
The September 9 financing table, and how Solstice's $105 million at signing actually splits
The new permanent FDA leadership roster, and the question it poses for the variance arc
The 13 ticker day two market table, official exchange closes
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The IOU ledger: the week's five withheld datasets ranked by whether they carry a due date, and the one whose clock a competitor just set
💊 Why the FDA's surrogate ledger and the market's are diverging this week, and which one the next contested file will actually trade on
📊 The NewCo math inside Solstice's $105 million at signing, and what it says about who really holds China asset risk
🎯 Plus the week's coming catalysts, with the full calendar returning Friday
Three sponsors said met in one day this week, and none of them said by how much. Today's tape barely moved, which is what waiting looks like. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →